Advertisement

Reactions Weekly

, Volume 1695, Issue 1, pp 78–78 | Cite as

Bortezomib/rituximab

Thrombocytopenia and anaemia aggravation: 2 case reports
Case report

Reference

  1. Zilioli VR, et al. Rituximab plus bortezomib still represents an effective treatment option for patients with relapsed or refractory mantle cell lymphoma. Blood 130 (Suppl. 1): no pagination, Dec 2017 [abstract] - ItalyGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations